LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.420-0.460 for the period, compared to the consensus EPS estimate of 0.420. The company issued revenue guidance of $52.7 million-$54.7 million, compared to the consensus revenue estimate of $52.4 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.820-1.910 EPS.
LeMaitre Vascular Stock Performance
LMAT traded down $1.24 during midday trading on Friday, reaching $85.01. 348,354 shares of the company were exchanged, compared to its average volume of 157,693. LeMaitre Vascular has a one year low of $44.27 and a one year high of $91.76. The stock has a market capitalization of $1.91 billion, a P/E ratio of 56.30, a PEG ratio of 2.63 and a beta of 0.89. The stock’s 50-day simple moving average is $82.69 and its 200 day simple moving average is $71.79.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The firm had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same quarter last year, the business earned $0.37 earnings per share. The company’s revenue was up 11.4% compared to the same quarter last year. On average, research analysts anticipate that LeMaitre Vascular will post 1.77 earnings per share for the current year.
LeMaitre Vascular Announces Dividend
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. Stifel Nicolaus raised LeMaitre Vascular from a hold rating to a buy rating and raised their price target for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. JMP Securities lifted their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a research report on Friday, May 3rd. StockNews.com lowered LeMaitre Vascular from a buy rating to a hold rating in a research report on Friday. Roth Capital raised LeMaitre Vascular to a strong-buy rating in a research report on Friday, May 31st. Finally, Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday. They issued a buy rating and a $105.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $86.50.
Get Our Latest Stock Report on LMAT
Insiders Place Their Bets
In other news, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director David B. Roberts sold 5,025 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.62, for a total value of $379,990.50. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,067,300.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold 127,437 shares of company stock valued at $10,076,242 in the last 90 days. 10.79% of the stock is currently owned by insiders.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
See Also
- Five stocks we like better than LeMaitre Vascular
- Earnings Per Share Calculator: How to Calculate EPS
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Technology Stocks Explained: Here’s What to Know About Tech
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- 5 discounted opportunities for dividend growth investors
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.